Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 24-02-2023
  • E-pubdatum
  • 24-02-2023
  • Bron
  • Medische Oncologie

Plaatsbepaling pembrolizumab voor stadium II/III triplenegatief mammacarcinoom

Lees online Download PDF

De commissie BOM heeft naar aanleiding van de KEYNOTE-522-studie1 een voorlopig positief advies (zie verderop in dit tijdschrift) gegeven voor … Verder lezen “Plaatsbepaling pembrolizumab voor stadium II/III triplenegatief mammacarcinoom”

  1. Schmid P, Cortes J, Dent R, et al. Eventfree survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386(6):556-7.
  2. EBCTCG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patientlevel meta-analysis of 37.298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440–52.
  3. Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxanebased neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019;30(8):1279-88.
  4. Mittendorf E, Zhang H, Barrios C, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with earlystage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial, Lancet 2020; 396(10257), 1090-100.
  5. Masuda N, Lee S, Ohtan S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376:2147-59.
  6. Geyer C, Sikov W, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol 2022;33(4):384-94.
  7. Bonadio R, Tarantino P, Testa, L et al. Management of patients with early-stage triple-negative breast cancer following pembrolizumabbased neoadjuvant therapy: What are the evidences?. Cancer Treat Rev 2022;110:102459.
  8. Liu J, Blake S, Yong M, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov 2016;6(12):1382-99.
  9. Versluis J, Long G, Blank C, et al. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 2020;26(4):475-84.
Lees meer